Effects of Inulin and Arabinoxylan on Satiety, Energy/Food Intake and Changes in the Human Gut Microbiota

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

33 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2018-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This proposed randomized, double blinded 12 week crossover human feeding study aims to investigate the effects of consuming a composite drink of inulin and arabinoxylan on satiety by measuring appetite biomarkers such as subjective satiety, energy/food intake and changes in the human gut microbiota in healthy weight males (22 to 24.9kg/m2)

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inulin,SCFA Production and Metabolic Response

NCT02009670

Type 2 Diabetes Mellitus Obesity

COMPLETED NA

Acute Effects of Coffee Beverage on Postprandial Inflammation and Oxidative Stress - A Pilot Study

NCT02174640

Overweight Obese Healthy

COMPLETED NA

Evaluation of New Beverages Rich in Bioactive Compounds for the Modulation of Energetic Metabolism in Overweight Adults

NCT04016337

Obesity Inflammation Insulin Sensitivity

COMPLETED NA

Measuring Effects of Prebiotics on Human Behavior and Cognition

NCT04055246

Prebiotics and Human Behavior and Cognition

COMPLETED NA

Bioavailability and Beneficial Properties of Coffee and Cocoa Bioactive Compounds

NCT03166540

Diet Modification Cardiovascular Risk Factor Nutritional and Metabolic Diseases

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Research that focuses on the mechanisms involved in appetite regulation is topical given the emergence of the worldwide obesity epidemic. Understanding the physiological processes associated with the onset of obesity is essential for the development of effective anti-obesity strategies. There is evidence that people who consume a diet high in non-starch polysaccharides (NSPs) have a lower body mass index (BMI) than those that do not.

A 2009 review of fibre and satiety by Bridget Benelam, 2009 focused on different types of fibre and the significant impact they may have on satiety and/or energy intake, through fermentation of fibre such as non starch polysaccharides in the colon by gut bacterial groups such as Bifidobacterium. non starch polysaccharides and other fibre sources are poorly digested by human enzymes in the small intestine but are degraded by large groups of bacteria in the large bowel. One of the beneficial outcomes of this fermentation of fibre that gut bacteria produce of metabolites called short chain fatty acids (SCFA) thought to affect appetite regulation by stimulating production of satiety hormones that can help you feel full. Acetate and propionate are two of these metabolites highlighted as potential mediator of satiety.

Some fibres are called prebiotics as they act as selective sources for beneficial gut bacteria. However Western populations do not consume natural prebiotics in high quantities in their diet and the overall intake of fibre is also low. Therefore, in this study, the investigators aim to utilise a mixture of prebiotics in order to increase the growth and/or activity of commensal gut bacteria and SCFA production in human volunteers and to assess the effects of consumption on satiety.

Testing the impact of a composite mix of inulin and arabinoxylan in a human study will help determine the effect it has on appetite regulation, ad libitum food intake, SCFA production, anthropometric measurements, cognitive state (e.g. mood) and composition of the gut microbiota.

The study design is a 12 week randomized, human feeding study, with a crossover design testing a composite mix of inulin and arabinoxylan against an equivalent energy matched (kcal) maltodextrin control drink in 33 healthy weight (22 to 24.9kg/m2) males aged between 21-55. Volunteers will be enrolled to treatment or placebo for four weeks, with a four week wash out before the crossover. the primary endpoint, satiety following a test meal challenge will be measured on four occasions throughout the study. Anthropometry measures, dietary intake, body weight and blood pressure will be monitored throughout the study. Faecal and urine will be collected at baseline and at the end of each treatment period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Overweight and Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

inulin

Investigating the satiating effects of consuming 4g/d inulin (Fruitafit IQ by CHIMAB)

Group Type EXPERIMENTAL

inulin

Intervention Type OTHER

Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g

non inulin and arabinoxylan

investigating the satiating effects of a control drink (2.6g/d maltodextrin)

Group Type NO_INTERVENTION

No interventions assigned to this group

arabinoxylan

Investigating the satiating effects of consuming 4g/d arabinoxylan (Medium Chain Naxus, BioActor b.v)

Group Type EXPERIMENTAL

arabinoxylan

Intervention Type OTHER

Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

inulin

Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g

Intervention Type OTHER

arabinoxylan

Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Inulin (Fruitafit IQ) arabinoxylan (Naxus)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males
* 21-55 years old
* Body Mass Index (BMI) 19.5-24.5kg/m2
* Overall healthy
* Weight Stable (\<3 kg change in the past 4 months, before the trial).

Exclusion Criteria

* Smokers
* drink more than 28 units of alcohol per week (i.e. not more than 14 pints of beer or 28 small glasses of wine)
* Restricted diet such as weight loss, vegetarian/vegan or taking dietary supplements such as prebiotics (such as oligosaccharides ie Fructo-oligosaccharides (FOS), galacto-oligosaccharides (GOS) or probiotics (ie Actimel)), not eating breakfast and \>25g/d dietary fibre consumption as well as those with food allergies
* Gastrointestinal procedure or surgery in the past three months.
* Gastrointestinal disorders: celiac disease, Intestinal Bowel Disease (IBD), irritable bowel syndrome (IBS), chronic constipation, diverticulitis or a history of chronic constipation, diarrhoea, or other chronic gastrointestinal complaints
* Disorders of swallowing, severe dysphagia to food or pills.
* Appetite modulator drugs: orlistat, sibutramine, rimonabant.
* Mood disorder medications: antidepressants, lithium.
* Chronic metabolic conditions: diabetes, hepatic disease, gout, kidney, thyroid or coagulation disease.
* Psychiatric disorder: severe depression, bulimia, anorexia, schizophrenia, bipolar disorder.
* Pregnancy
* Others: oral antidiabetics, insulin, digoxin, thyroid hormones, antibiotics, steroids or immunosuppressants, recreational substances.
* Use of implanted or portable electro-mechanical device such as cardiac peacemaker or infusion pump.
* Blood donor in the past 3 months.

Minimum Eligible Age

21 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No